Cipla inks definitive agreement to acquire 60% stake of Jay Precision Pharmaceuticals

13 Feb 2015 Evaluate

Cipla has signed a definitive agreement to acquire 60% stake of Jay Precision Pharmaceuticals, Mumbai, from the existing shareholders, for a cash consideration of Rs 96 crore. Jay Precision is an existing supplier of respiratory devices to the company and has a state of the art manufacturing facility at Vasai, Maharashtra. Considering company’s leading position in inhalation therapy, this transaction is aimed at integrating the value chain and will serve as platform for development of next generation respiratory devices.

The pharmaceutical undertaking of Jay Precision Products (India) was demerged into Jay Precision effective January 01, 2014. The turnover of Jay Precision for the year ended March 31, 2014 was Rs 30 crore. The transaction is expected to be completed by end of this financial year, subject to completion of certain conditions precedent.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally.

Cipla Share Price

1520.55 -0.65 (-0.04%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×